Scilex Holding (SCLXW) Goodwill & Intangibles (2021 - 2026)
Scilex Holding (SCLXW) recorded quarterly Goodwill & Intangibles of $73.3 million in Q1 2026, down 30.38% quarter-over-quarter from $105.3 million in Q4 2025, and down 1.31% on a YoY basis from $74.3 million in Q1 2025.
Scilex Holding (SCLXW) Goodwill & Intangibles (2021 - 2026) Analysis & Trends
Scilex Holding's Goodwill & Intangibles history runs 6 years deep, the most recent figure standing at $73.3 million for Q1 2026.
- In Q1 2026, Goodwill & Intangibles fell 1.31% year-over-year to $73.3 million; the TTM figure through Mar 2026 stood at $73.3 million (down 1.31% YoY), while the FY2025 annual figure was $105.3 million, up 41.74% from the prior year.
- Goodwill & Intangibles was $73.3 million for Q1 2026 at Scilex Holding, down from $105.3 million in the prior quarter.
- In the past five years, Goodwill & Intangibles ranged from a high of $105.3 million in Q4 2025 to a low of $5.0 million in Q1 2022.
- Historically, Goodwill & Intangibles has averaged $53.3 million across 5 years, with a median of $52.0 million in 2023.
- The sharpest annual moves came in 2023 and 2025: Goodwill & Intangibles jumped 1385.62% in 2023, then tumbled 39.5% in 2025.
- A 5-year view of Goodwill & Intangibles shows it stood at $54.1 million in 2022, then surged by 37.29% to $74.3 million in 2023, then changed by 0.0% to $74.3 million in 2024, then soared by 41.74% to $105.3 million in 2025, then tumbled by 30.38% to $73.3 million in 2026.
- The last three Goodwill & Intangibles figures came in at $73.3 million (Q1 2026), $105.3 million (Q4 2025), and $43.9 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Gsk | 93,699,046.73 Bn | 93,699,041.77 Bn | 7.76 Bn |
| 2 | Eli Lilly | 1,012.06 Bn | 1,006.77 Bn | 16.22 Bn |
| 3 | Johnson & Johnson | 560.67 Bn | 538.62 Bn | 15.96 Bn |
| 4 | AbbVie | 402.20 Bn | 392.85 Bn | 10.78 Bn |
| 5 | Merck | 298.59 Bn | 292.94 Bn | 12.09 Bn |
| 6 | Amgen | 188.77 Bn | 176.74 Bn | 5.87 Bn |
| 7 | Gilead Sciences | 160.22 Bn | 152.49 Bn | 5.52 Bn |
| 8 | Pfizer | 148.19 Bn | 135.42 Bn | -1.21 Bn |
| 9 | Bristol Myers Squibb | 116.72 Bn | 106.26 Bn | 8.07 Bn |
| 10 | Scilex Holding | - | - | 4.15 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 73.29 Mn |
| Dec 31, 2025 | 105.26 Mn |
| Sep 30, 2025 | 43.90 Mn |
| Jun 30, 2025 | 44.94 Mn |
| Mar 31, 2025 | 74.26 Mn |
| Dec 31, 2024 | 74.26 Mn |
| Sep 30, 2024 | 46.94 Mn |
| Jun 30, 2024 | 74.28 Mn |
| Mar 31, 2024 | 48.96 Mn |
| Dec 31, 2023 | 74.26 Mn |
| Sep 30, 2023 | 50.99 Mn |
| Jun 30, 2023 | 52.04 Mn |
| Mar 31, 2023 | 74.28 Mn |
| Dec 31, 2022 | 54.09 Mn |
| Sep 30, 2022 | 5.00 Mn |
| Jun 30, 2022 | 5.00 Mn |
| Mar 31, 2022 | 5.00 Mn |
| Dec 31, 2021 | 52.30 Mn |